Medical devices and diagnostics play a crucial role in the detection, prevention and treatment of a wide variety of health issues. At StatForce, we recognize that the clinical trial and approval process for a device or diagnostic is different than the drug development landscape. To help navigate the terrain, we bring a top device CRO team of experienced and qualified professionals to support your study in this cutting-edge market segment.

StatForce has a deep understanding of the regulatory requirements, operational guidelines, and safety considerations to successfully advance your medical device or diagnostic product. We have an impressive record in conducting pilot, pivotal, and post-approval studies. StatForce has the expertise and resources to support your unique and complex developmental needs. For success in your medical device or diagnostic study – and to improve the health and extend the lives of patients worldwide – StatForce is your full service CRO partner.

Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, parasites or fungi. They are often referred to as transmissible diseases, communicable diseases, or contagious diseases. No matter the form of transmission, these diseases can affect our world in pandemic proportions.

StatForce continues its strong commitment to stop the spread of infectious diseases. As a full-service CRO, we work with sponsors and investigators to manage, prevent, and find cures. Our teams are adaptable, knowledgeable, and cohesive, with strong site relationships to help deliver the best infectious disease CRO services. We have the extensive experience with related treatments and vaccines – including antivirals, antibiotics and antifungal compounds – to deliver pertinent, practical knowledge to move your trials forward.

StatForce experience as a Central Nervous System (CNS) CRO providing clinical research is unrivaled. From neurology to analgesia and addiction drug development, our expertise spans translational medicine, registry with pharmaco-economic intent. Whether your compound is an original small molecule, injectable large molecule or biosimilar – our CNS experts are true specialists.

Developments in Cardiovascular research are resulting in a reduction of mortality and morbidity while new trends move toward identifying innovative study end points. Thus, new clinical trials related to Cardiovascular will need to be more nuanced.

The strategy for groundbreaking studies focused on Cardiovascular would be creating study designs with alternative end points, which are more nuanced than the traditional mortality end point and are both quantifiable and relevant to the needs of patients and to the interests of other medical care stakeholders.

Our history in cardiovascular research spans thousands of sites globally and has gathered data from hundreds of thousands of patients. This extensive history, combined with our capacity for innovative trial design and an understanding of cardiovascular research, makes us your ideal CRO partner in creative and strategic trial design for your heart failure study.

For the complexities of your hematological cancer study, StatForce Trials can apply a multidisciplinary approach with years of experience in oncology therapeutics research, including work on hematologic indications and therapies. As a full service CRO can provide any or all trial-related services, and we are just the right size to maintain the flexibility a complex trial requires and give your project the keen attention you expect.

We have diverse experience in various classes of small molecules and biologics across a broad spectrum of cancers, including lung, breast, skin, leukemias and multiple myeloma. Our deep experience goes even further, including:

• Radiopharmaceuticals
• Biosimilar medicines
• Cancer supportive care medications